ESC Heart Failure

Article	Citations
Establishing a novel model to assess exercise capacity in chronic heart failure based on stress echocardiography	90
Calcium channel blockers and clinical outcomes in patients with continuous‐flow left ventricular assist devices	68
Prediction of cardiac events with non‐contrast magnetic resonance feature tracking in patients with ischaemic cardiomyopathy	66
	63
Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study	62
Corrigendum	61
Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report	58
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure	57
Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation	56
Systolic dysfunction and mortality in critically ill patients: more data are needed to believe in this association!	54
Blood perfusion status is important in the prognosis of ventricular aneurysm complicated by ventricular septal rupture	53
Editors' highlight picks from 2023 in ESC heart failure	53
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan	53
Cardiac involvement in patients recovering from Delta Variant of COVID‐19: a prospective multi‐parametric MRI study	49
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry	43
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit	43
Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China	42
Cardiogenic shock requiring VA‐ECMO therapy in scorpionism‐induced myocarditis	42
Circ_0001206 regulates miR‐665/CRKL axis to alleviate hypoxia/reoxygenation‐induced cardiomyocyte injury in myocardial infarction	41
Oral iron supplementation in patients with heart failure: a systematic review and meta‐analysis	39
Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy	38
Reductions in renin‐angiotensin system inhibitors following hospitalization for heart failure	38
Health‐related quality of life among transthyretin amyloid cardiomyopathy patients	38
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices	37
Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction	37

Meta‐analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy	37
Atrial fibrillation ablation in patients with arrhythmia‐induced cardiomyopathy: a prospective multicentre study	37
Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure	37
Meta‐Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease	37
Risk classification for long‐term mortality among patients with acute heart failure: China PEACE 4YMortality	36
Long‐term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely	36
Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach	36
	36
Early achievement of walkability after cardiac surgery and the risk of cardiovascular disease after hospital discharge	35
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator	35
Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study	35
Sex differences in the impact of frailty on patients with heart failure: A retrospective cohort study	35
Explainable machine learning and online calculators to predict heart failure mortality in intensive care units	34
The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation	34
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	34
Issue Information	33
Intense optimization of oral therapy rapidly restores respiratory function in worsening heart failure patients	33
Prognostic value of left atrial strain in acute and chronic heart failure: A meta‐analysis	32
Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI	32
Discordance between estimated and measured changes in plasma volume among patients with acute heart failure	31
Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire	31
Real‐time pulmonary artery pressure monitoring in heart failure patients: an updated cost‐effectiveness analysis	31
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients	31
Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019	31
Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis	30
Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non‐invasive technique	30
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	30
Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines	30
Heart failure and trimethylamine N‐oxide: time to transform a ‘gut feeling’ in a fact?	30
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care	30
Increased acylcarnitines in infant heart failure indicate fatty acid oxidation inhibition: towards therapeutic options?	29
Predictive value of global longitudinal strain by left ventricular ejection fraction	29
Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine	29
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance	29
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	29
Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome	29
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease	28
Acylation‐stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy	28
Correction to “Understanding the variability in red cell and plasma volume combinations can help guide management in heart failure”	28
Delay in cardiology consultation after primary care physician referrals in heart failure: Clinical implications	28
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study	28
Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis	28
Soluble neprilysin and survival in critically ill patients	28
Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study	27
SARS‐CoV‐2‐related Multisystem Inflammatory Syndrome in Adult complicated by myocarditis and cardiogenic shock	27
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction	27
Sex‐specific associations of cardiorespiratory fitness and galectin‐3 in the general population	27
Letter to the editor regarding ‘Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis’	27
Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight	27
Takotsubo cardiomyopathy during armed conflict: A case series	27

Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey	27
Congestion, decongestion, renal function and diuretics in (ESC) heart failure	27
Advances in device‐based treatment of heart failure with preserved ejection fraction: evidence from clinical trials	27
Determinants of left ventricular function improvement for cardiac resynchronization therapy candidates	26
Left ventricular reverse remodelling as a promising strategy for resolving left ventricular thrombus	26
Angiographic classification of total occlusion and its implication on balloon pulmonary angioplasty	26
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM	26
Platelet count in heart failure patients undergoing left ventricular assist device	26
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction	26
Effects of homoarginine supplementation on heart and skeletal muscle of rats with heart failure with preserved ejection fraction	25
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study	25
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation	25
Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA‐R)	24
Acute myocarditis according to age: Presentation, management and early outcomes	24
Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Ger	24
Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery	24
Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation	24
Gender‐specific prevalence and trend of heart failure in China from 1990 to 2019	24
Human epididymis protein 4 is a useful predictor of post‐operative prognosis in patients with severe aortic stenosis	24
Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China	24
Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction	24
Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017	23
Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure	23
Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta‐analysis	23
Prognostic value of left atrial reverse remodelling in patients hospitalized with acute decompensated heart failure	22
Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis	22
A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting	22
Increasing home‐time after a first diagnosis of heart failure in Sweden, 20 years trends	22
Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator	22
Issue Information	22
Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction	22
Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy	22
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial	21
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial	21
Time‐domain heart rate variability features for automatic congestive heart failure prediction	21
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode	21
Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction	21
Performance of non‐invasive myocardial work to predict the first hospitalization for de novo heart failure with preserved ejection fraction	21
Nutritional status during hospitalization is associated with the long‐term prognosis of patients with heart failure	21
Changes over time in patient‐reported outcomes in patients with heart failure	21
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis	21
Outcomes after heart transplantation in patients with cardiac sarcoidosis	21
A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation	21
Adaptive versus maladaptive right ventricular remodelling	21
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure	20
Impact of B‐lines‐guided intensive heart failure management on outcome of discharged heart failure patients with residual B‐lines	20
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study	20
Considerations for drug trials in hypertrophic cardiomyopathy	20
Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience	20
Human myocardial mitochondrial oxidative capacity is impaired in mild acute heart transplant rejection	20
Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real‐world experience	20
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort	20
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta‐analysis	20
Sex‐based differences in referral of heart failure patients to outpatient clinics: a scoping review	19
Biomarker prognostication across Universal Definition of Heart Failure stages	19
Adequate immune response after SARS‐CoV‐2 infection and single dose vaccination despite rapid heart transplantation	19
Letter regarding the article “Hypocapnia is an independent predictor of in‐hospital mortality in acute heart failure”	19
The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea	19
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review	19
Genotype is associated with left ventricular reverse remodelling and early events in recent‐onset dilated cardiomyopathy	19
Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review	19
Response to Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	19
Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction	19
Temporal profiling of M‐TEER‐related complications	19
Variability in estimated glomerular filtration rate and patients' outcomes in a real‐world heart failure population	19
Cognitive transitions based on functional status in older adults with heart failure: a population‐based study	19
Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis	19
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure	19
Corrigendum	19
Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction	19
Biomarkers in heart failure: Traditional and emerging indicators for prognosis	19
Clinical application and immune infiltration landscape of stemness‐related genes in heart failure	18
Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure	18
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study	18
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review	18
Investigating the relationship between FRailty And Quality of LIfe in patients with heart faiLure and CKD (FRAIL study)	18
Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography	18
Prognostic impact of heart failure admission in survivors of acute myocardial infarction	18
Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair	18
A meta‐analysis of the relationship between glycaemic variability and the mortality of patients with heart failure	18

Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure	18
Narrative synthesis of the effectiveness and characteristics of heart failure disease self‐management support programmes	18
E prostanoid receptor‐3 promotes oxidized low‐density lipoprotein‐induced human aortic smooth muscle cells inflammation	18
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	18
Diabetes and treatment of chronic heart failure in a large real‐world heart failure population	18
Severe aortic insufficiency‐induced cardiogenic shock treated with left atrial VA‐ECMO and emergent valve‐in‐valve TAVR	18
Pre‐emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm	18
Association of iron deficiency with incident cardiovascular diseases and mortality in the general population	18
Efficacy and safety of digital therapeutics‐based cardiac rehabilitation in heart failure patients: a systematic review	18
Cardiovascular vs. non‐cardiovascular deaths after heart failure hospitalization in young, older, and very old patients	18
The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure	18
Clinical performance and quality measures for heart failure management in China: the China‐Heart Failure registry study	18
Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction	18
Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”	17
Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	17
S2I2N0–3 score predicts short‐ and long‐term mortality and morbidity in HFrEF: a post‐hoc analysis of the GUIDE‐IT trial	17
Impact of the COVID‐19 pandemic on management and outcomes of patients with acute heart failure	17
Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation	17
IgM‐enriched immunoglobulin as adjuvant therapy for heart transplant after infection of left ventricular assist devices	17
Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients	17
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis	17
Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure	17
The association between cardiac involvement and long‐term clinical outcomes in patients with Duchenne muscular dystrophy	17
Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia	17
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence	17
Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study	17
A nationwide study of temporal trends of cause‐specific hospital readmissions in patients with heart failure	17
Low‐density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction	17
Is ischaemic heart failure an autoimmune disease?	17
Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides	16
Eniluracil blocks AREG signalling‐induced pro‐inflammatory fibroblasts of melanoma in heart failure	16
Issue Information	16
Issue Information	16
Atrial‐secondary tricuspid regurgitation: a better prognosis in early stage heart failure, but not in late stage	16
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF	16
Coronary angiography in patients with acute heart failure: from the KCHF registry	16
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure	16
Interpretation of elevated baseline concentrations and serial changes of high‐sensitivity cardiac troponin T in confirmed muscular dystrophies	16
Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure	16
Issue Information	16
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?	15
Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre	15
Successful percutaneous treatment of late outflow graft failure of the left ventricular assist device: a long‐term follow‐up	15
Paediatric heart transplantation during the COVID‐19 pandemic in Iran: single‐centre experience	15
Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients	15
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters	15
Multiorgan characterization of inflammasome component expression in a rat model of advanced heart failure	15
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry	15
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure	15
Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure	15
Prognostic implications of functional tricuspid regurgitation in asymptomatic degenerative mitral regurgitation	15
Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation	15
Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study	15
Integrin beta‐like 1 is regulated by DNA methylation and increased in heart failure patients	15
Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes	15
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events	15
Relationship between haemodynamic indicators and haemogram in patients with heart failure	15
Effect of early intervention on short‐term prognosis of patients with myocardial injury induced by acute carbon monoxide poisoning	15
Estimated pulse wave velocity and risk of new‐onset heart failure	15
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure	15
Application of recommended therapies among patients with heart failure during the Syrian conflict: reality and barriers	14
In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure	14
Decreased endogenous nitric oxide production in acute decompensated heart failure with a reduced ejection fraction	14
Prognostic value of high‐sensitivity cardiac troponin I in patients with non‐ischaemic heart failure: insights from China	14
Prognostic impact of beta‐blocker use by N‐terminal pro‐brain natriuretic peptide level in acute heart failure patients	14
The double anaerobic threshold in heart failure: MECKI score database overview	14
Prognostic effect of systematic geriatric assessment on patients with acute heart failure	14
Transition from asymptomatic to symptomatic systolic chronic heart failure: rationale and design of TransitionCHF	14
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy	14
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI	14
HFA of the ESC position paper on the management of LVAD‐supported patients for the non‐LVAD specialist healthcare provider Part 3: at the hospital and discharge	14
Decoding cardiogenic shock: assessing shock index and its variants as prognostic indicators for in‐hospital mortality	14
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i	14
Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop	14
Neutrophil‐to‐lymphocyte ratio: link to congestion, inflammation, and mortality in outpatients with heart failure	14
Ten year age‐ and sex‐specific temporal trends in incidence and prevalence of heart failure in Västra Götaland, Sweden	14
Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study	14
Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction	14
ST‐segment depression and left ventricular systolic function recovery post‐atrial fibrillation ablation in heart failure	14
Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients	14
The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles	14
Susceptibility to infections and adaptive immunity in adults with heart failure	14
Trametinib alters contractility of paediatric Noonan syndrome‐associated hypertrophic myocardial tissue slices	14
Haemodynamic changes of interatrial shunting devices for heart failure: a systematic review and meta‐analysis	14
The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure	14
Increased calcification by erythrophagocytosis in aortic valvular interstitial cells	14
U‐shaped association between body mass index and ejection fraction in intensive care unit patients with heart failure	14
Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis	14
Long term changes in health‐related quality of life for people with heart failure: the ECHOES study	14
A case of biopsy‐proven inflammatory dilated cardiomyopathy following heterologous mRNA‐1273 third‐dose immunization	14
Correction to “Impact analysis of heart failure across European countries: an ESC‐HFA position paper” and “Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory he	14
Cardiac arrest caused by coronary occlusion during transcatheter aortic valve implantation: a unique cause	14
Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy	14
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	14
Transjugular tricuspid valve‐in‐ring replacement using the novel system under three‐dimensional printing guidance	13